Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Myo Maung Maung Swe and Htet Htet Aung from our MOCRU unit in Myanmar were awarded grants by the International Society for Infectious Diseases and Wellcome. Myo Maung will study antibiotics use and antimicrobial resistance public awareness in Myanmar; Htet Htet will conduct a study on Ethical challenges when offering pregnant women with Hepatitis B short course treatment to prevent transmission.

Dr Myo Maung Maung Swe and Htet Htet Aung

Dr Myo Maung Maung Swe (left), Clinical Researcher and DPhil student at MOCRU, was awarded in August an International Society for Infectious Diseases (ISID) research grant, a signature ISID program that funds infectious disease researchers from LMIC countries with the greatest burden of infectious disease. Myo Maung, a clinical researcher at MOCRU for 3 years, was awarded the ISID research grant to conduct the study Antibiotics use and antimicrobial resistance (AMR) public awareness survey in Myanmar. Myo plans to conduct the study, which aims to understand self-reported antibiotic use, public knowledge of antibiotics and the awareness of antibiotic resistance, in two regions of Myanmar, as yet to be determined. The team will collect data Dec 2018-Jan 2019 and hopes to publish results by April 2019.

That same month, MOCRU Clinical Research Assistant Htet Htet Aung (right) was awarded an Ethox Global Health Bioethics Network (GBHN) Bursary Award. GBHN is funded by a Wellcome Trust Strategic Award aiming to conduct ethics research and improve capacity building across the Wellcome Trust Major Overseas Programmes. Htet Htet, who has worked as a clinical research assistant in MOCRU for a year, will use the GBHN Bursary to conduct the study Ethical challenges related to offering pregnant women with chronic Hep B short course treatment with Tenofovir disoproxil fumarate to prevent vertical transmission in Myanmar. Htet Htet hopes to start the study mid-Oct, once she gets OxTREC and local Ethics Committee approval, and publish results in early June 2019. The study will be conducted at Central Women’s Hospital, Yangon.

Similar stories

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19

@Oxford Research

Convalescent plasma has been widely used as a treatment for COVID-19 but to date there has been no convincing evidence of the effect of convalescent plasma on clinical outcomes in patients admitted to hospital with COVID-19. Recruitment to the convalescent plasma arm of the RECOVERY trial has now closed. The preliminary analysis based on 1873 reported deaths among 10,406 randomised patients shows no significant difference in the primary endpoint of 28-day mortality. Recruitment to all other treatment arms – tocilizumab, aspirin, colchicine, and Regeneron’s antibody cocktail – continues as planned.

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

@Oxford MORU Publication Research

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

Receiving and responding to community feedback during health system crises in Kenya

KWTRP Publication Research

The responsiveness of a health system is one of its goals, alongside fairness in financing and outcomes. Listening and responding to the public can make a health system stronger and fairer. However, responsiveness is likely to be undermined, especially for vulnerable and marginal populations, in periods of crises such as disease outbreaks. In the current COVID-19 crisis, there has been more focus on health system control interventions, with minimal consideration of community views. KWTRP colleagues in Kenya consider community engagement and citizens feedback channels, concerns raised by the public and how they were handled, and highlight lessons learned.

RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19

@Oxford Research

Established in March 2020, the RECOVERY trial tests a range of potential treatments for COVID-19, including azithromycin, a widely used antibiotic that also reduces inflammation. The azithromycin arm of the trial was established to determine whether or not the drug has a meaningful benefit among patients hospitalised with COVID-19. A preliminary analysis shows no significant difference in the primary endpoint of 28-day mortality; there was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay.

The COVID-19 vaccine: do we know enough to end the pandemic?

@Oxford MORU

Blog by Rima Shretta. Preliminary efficacy results from three vaccine candidates currently in Phase 3 trials have shown an efficacy of more than 90% against the development of symptomatic COVID-19. While these results are promising, all vaccines are in relatively early stages of testing. A comprehensive and transparent roadmap is urgently needed, to determine how limited doses of the first vaccines to be licensed will be distributed, together with which groups will initially be prioritized.

New study on the risk of Plasmodium vivax parasitaemia after Plasmodium falciparum malaria

@Oxford MORU Publication Research

A new study quantifying the high risk of Plasmodium vivax parasitaemia after treatment of Plasmodium falciparum malaria aims to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy with a hypnozoitocidal antimalarial drug, would be most beneficial.